ResearcherDankook UniversityNo recent work listed
Yeon-Sun Seong
Matched on ORCID iD 0000-0002-4743-8048; OpenAlex author ID A5057283425.
Their work
- Papers
- 10 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 7
2012: 4 papers · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 2 papers
Papers 10
- Anaplastic lymphoma kinase inhibitor NVP‑TAE684 suppresses the proliferation of human pancreatic adenocarcinoma cells. Last author DOI 10.3892/or.2021.7979↗
- Doxycycline potentiates the anti-proliferation effects of gemcitabine in pancreatic cancer cells. Co-author PMID 34354858↗
- Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells. Last author DOI 10.3390/antiox6030052↗
- Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Co-author DOI 10.3892/ijo.2013.2229↗
- Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells. Last author DOI 10.3892/ijo.2014.2357↗
- Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. Co-author DOI 10.1111/jcmm.12101↗
- Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318230f71a↗
- Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells. Co-author DOI 10.3892/ijo.2012.1516↗
- BML-275, an AMPK inhibitor, induces DNA damage, G2/M arrest and apoptosis in human pancreatic cancer cells. Co-author DOI 10.3892/ijo.2012.1672↗
- Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. Last author PMID 22399597↗
Closest collaborators
The 7 strongest of 7 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Hong-Quan Duong · 7 shared papers, 2012–2021
- Paper Anaplastic lymphoma kinase inhibitor NVP‑TAE684 suppresses the proliferation of human pancreatic adenocarcinoma cells. DOI 10.3892/or.2021.7979↗
- Paper Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells. DOI 10.3390/antiox6030052↗
- Paper Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant … DOI 10.3892/ijo.2014.2357↗
- Yong Weon Yi · 5 shared papers, 2012–2021
- Paper Doxycycline potentiates the anti-proliferation effects of gemcitabine in pancreatic cancer cells. PMID 34354858↗
- Paper Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant … DOI 10.3892/ijo.2014.2357↗
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Young Bin Hong · 5 shared papers, 2012–2021
- Paper Doxycycline potentiates the anti-proliferation effects of gemcitabine in pancreatic cancer cells. PMID 34354858↗
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Paper Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. DOI 10.1097/mpa.0b013e318230f71a↗
- Insoo Bae · 7 shared papers, 2012–2014
- Paper Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant … DOI 10.3892/ijo.2014.2357↗
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Paper Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. DOI 10.1097/mpa.0b013e318230f71a↗
- The-Hung Dang · 1 shared paper, 2021
- Seunghoon Oh · 1 shared paper, 2017
- Yeon Jeong Kim · 2 shared papers, 2012–2013
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.